SAB Biotherapeutics
SABS
42 hedge funds and large institutions have $24.5M invested in SAB Biotherapeutics in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 5 closing their positions.
915% more capital invested
Capital invested by funds: $2.41M → $24.5M (+$22.1M)
180% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 5
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
24% more funds holding
Funds holding: 34 → 42 (+8)
3.13% more ownership
Funds ownership: 0.73% → 3.86% (+3.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$7.7M |
| 2 |
RI
RTW Investments
New York
|
+$7.7M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$3.84M |
| 4 |
SC
Sessa Capital
New York
|
+$3.84M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$1.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
-$46K |
| 2 |
BCM
Brookstone Capital Management
Wheaton,
Illinois
|
-$17.4K |
| 3 |
LP
LGL Partners
Philadelphia,
Pennsylvania
|
-$14.5K |
| 4 |
SFC
Strategic Financial Concepts
San Antonio,
Texas
|
-$9.47K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$4.21K |
SABS Hedge Fund Activity: Q4 2023 in Review
42 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q4 2023, worth a combined $24.5M — up 915% from $2.41M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new SABS positions and 5 closed out — a net gain of 9 holders — while 7 added to existing stakes and 3 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $7.7M. The largest seller was HighTower Advisors, exiting entirely with an estimated $46K sold.
- 42 institutional investors held SAB Biotherapeutics (SABS) as of Q4 2023, up from 34 in Q3 2023.
- Funds reported $24.5M of SAB Biotherapeutics stock for Q4 2023, up 915% quarter-over-quarter.
- 14 funds opened new SAB Biotherapeutics positions in Q4 2023 and 5 closed out, a net change of +9 holders.
- The largest SAB Biotherapeutics buyer in Q4 2023 was BVF Inc, an estimated $7.7M added.
- The largest SAB Biotherapeutics seller in Q4 2023 was HighTower Advisors, an estimated $46K sold.
Based on aggregated 13F filings for Q4 2023.